$HIMS is shaking up the pharma space, challenging $NVO’s patents in a high-stakes bet that could disrupt the weight loss market.
Both $NVO and $LLY face significant downside risk if litigation goes against them, making this a fascinating clash between nimble disruptors and Big Pharma.
Meanwhile, $MGM is quietly reducing its float, repurchasing 5.5% of shares in a single quarter, signaling confidence amid broader market volatility.
Investors should watch legal battles and corporate capital moves alike for asymmetric opportunities.
1. $Hims & Hers Health Inc.(HIMS)$
My gut feeling is that $HIMS is playing the ultimate disruption card.
They’re pushing so hard Novo sues, which ultimately leads to Novo defending — and potentially invalidating — their patents.
We tend to take pharma patents at face value as a moat and some kind of validation of what Big Pharma has done.
In reality, patents are rarely challenged and most/many wouldn’t hold up in court.
I think Hims is betting Novo will either cave in a settlement or they go all the way to the finish line and blow up the weight loss business.
2. $Novo-Nordisk A/S(NVO)$ VS $Eli Lilly(LLY)$
$NOVO and $LLY have a LOT more to lose than $HIMS here.
That's what makes this situation so interesting. How much do you risk a $24 billion business with a 5-year half life if you're $NOVO?
3. $MGM Resorts International(MGM)$
MGM repurchased 15 million shares in the last 3 months.
Shares outstanding were 273 million on Oct 27, 2025.
That's a 5.5% reduction in shares outstanding in a single quarter!!!
Comments